Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378619129> ?p ?o ?g. }
- W4378619129 endingPage "2974" @default.
- W4378619129 startingPage "2966" @default.
- W4378619129 abstract "Abstract Background Salivary duct carcinoma (SDC) is uncommon but is the most aggressive subtype of salivary gland carcinomas. The high positivity rate for human epidermal growth factor receptor 2 (HER2) led to an investigation of the efficacy of HER2‐targeted agents. Docetaxel‐PM (polymeric micelle) is a low‐molecular‐weight, nontoxic, biodegradable, and docetaxel‐loaded micellar formulation. Trastuzumab‐pkrb is a biosimilar to trastuzumab. Methods This was a multicenter, single‐arm, open‐label phase 2 study. Patients with HER2‐positive (immunohistochemistry [IHC] score of ≥2+ and/or HER2/chromosome enumeration probe 17 [CEP17] ratio of ≥2.0) advanced SDCs were enrolled. Patients received docetaxel‐PM (75 mg/m 2 ) and trastuzumab‐pkrb (8 mg/kg in the first cycle and 6 mg/kg in subsequent cycles) every 3 weeks. Primary end point was objective response rate (ORR). Results A total of 43 patients were enrolled. The best objective responses were partial response in 30 (69.8%) patients and stable disease in 10 (23.3%) patients, leading to an ORR of 69.8% (95% confidence interval [CI], 53.9–82.8) and a disease control rate of 93.0% (80.9–98.5). Median progression‐free survival, duration of response, and overall survival were 7.9 (6.3–9.5), 6.7 (5.1–8.4), and 23.3 (19.9–26.7) months, respectively. Patients with HER2 IHC score of 3+ or HER2/CEP17 ratio ≥2.0 demonstrated better efficacies compared to those with HER2 IHC score of 2+. Thirty‐eight (88.4%) patients experienced treatment‐related adverse events (TRAE). Because of TRAE, nine (20.9%), 14 (32.6%), and 19 (44.2%) patients required temporary discontinuation, permanent discontinuation, or dose reduction, respectively. Conclusions The combination of docetaxel‐PM and trastuzumab‐pkrb demonstrated promising antitumor activity with a manageable toxicity profile in HER2‐positive advanced SDC. Plain Language Summary Salivary duct carcinoma (SDC) is uncommon but is the most aggressive subtype of salivary gland carcinomas. SDC shares morphological and histological similarities with invasive ductal carcinoma of breast, which led to an investigation of hormonal receptor and human epidermal growth factor receptor 2 (HER2)/neu expression status in SDC. In this study, patients with HER2‐positive SDC were enrolled and treated with combination of docetaxel‐polymeric micelle and trastuzumab‐pkrb. Promising antitumor activities were shown with objective response rate of 69.8%, disease control rate of 93.0%, median progression‐free survival of 7.9 months, median duration of response of 6.7 months, and median overall survival of 23.3 months." @default.
- W4378619129 created "2023-05-29" @default.
- W4378619129 creator A5003219699 @default.
- W4378619129 creator A5005860749 @default.
- W4378619129 creator A5006027643 @default.
- W4378619129 creator A5011357776 @default.
- W4378619129 creator A5014103481 @default.
- W4378619129 creator A5015039301 @default.
- W4378619129 creator A5017844937 @default.
- W4378619129 creator A5017982180 @default.
- W4378619129 creator A5018558366 @default.
- W4378619129 creator A5024201724 @default.
- W4378619129 creator A5027019879 @default.
- W4378619129 creator A5034739279 @default.
- W4378619129 creator A5042529157 @default.
- W4378619129 creator A5053121208 @default.
- W4378619129 creator A5057867526 @default.
- W4378619129 creator A5059849795 @default.
- W4378619129 creator A5062362792 @default.
- W4378619129 creator A5066161983 @default.
- W4378619129 creator A5087021923 @default.
- W4378619129 date "2023-05-28" @default.
- W4378619129 modified "2023-10-17" @default.
- W4378619129 title "A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas" @default.
- W4378619129 cites W1580226419 @default.
- W4378619129 cites W1935910567 @default.
- W4378619129 cites W1977891261 @default.
- W4378619129 cites W2091010508 @default.
- W4378619129 cites W2159967578 @default.
- W4378619129 cites W2290704823 @default.
- W4378619129 cites W2623368390 @default.
- W4378619129 cites W2758417871 @default.
- W4378619129 cites W2791073967 @default.
- W4378619129 cites W2806209829 @default.
- W4378619129 cites W2901312960 @default.
- W4378619129 cites W2904920769 @default.
- W4378619129 cites W2947983979 @default.
- W4378619129 cites W2972850303 @default.
- W4378619129 cites W3042870182 @default.
- W4378619129 cites W3147820834 @default.
- W4378619129 cites W3157336873 @default.
- W4378619129 cites W3167933227 @default.
- W4378619129 cites W3176667585 @default.
- W4378619129 cites W4200097291 @default.
- W4378619129 cites W4205455562 @default.
- W4378619129 doi "https://doi.org/10.1002/cncr.34892" @default.
- W4378619129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37246414" @default.
- W4378619129 hasPublicationYear "2023" @default.
- W4378619129 type Work @default.
- W4378619129 citedByCount "0" @default.
- W4378619129 crossrefType "journal-article" @default.
- W4378619129 hasAuthorship W4378619129A5003219699 @default.
- W4378619129 hasAuthorship W4378619129A5005860749 @default.
- W4378619129 hasAuthorship W4378619129A5006027643 @default.
- W4378619129 hasAuthorship W4378619129A5011357776 @default.
- W4378619129 hasAuthorship W4378619129A5014103481 @default.
- W4378619129 hasAuthorship W4378619129A5015039301 @default.
- W4378619129 hasAuthorship W4378619129A5017844937 @default.
- W4378619129 hasAuthorship W4378619129A5017982180 @default.
- W4378619129 hasAuthorship W4378619129A5018558366 @default.
- W4378619129 hasAuthorship W4378619129A5024201724 @default.
- W4378619129 hasAuthorship W4378619129A5027019879 @default.
- W4378619129 hasAuthorship W4378619129A5034739279 @default.
- W4378619129 hasAuthorship W4378619129A5042529157 @default.
- W4378619129 hasAuthorship W4378619129A5053121208 @default.
- W4378619129 hasAuthorship W4378619129A5057867526 @default.
- W4378619129 hasAuthorship W4378619129A5059849795 @default.
- W4378619129 hasAuthorship W4378619129A5062362792 @default.
- W4378619129 hasAuthorship W4378619129A5066161983 @default.
- W4378619129 hasAuthorship W4378619129A5087021923 @default.
- W4378619129 hasConcept C121608353 @default.
- W4378619129 hasConcept C126322002 @default.
- W4378619129 hasConcept C143998085 @default.
- W4378619129 hasConcept C203092338 @default.
- W4378619129 hasConcept C204232928 @default.
- W4378619129 hasConcept C2776694085 @default.
- W4378619129 hasConcept C2779786085 @default.
- W4378619129 hasConcept C2781190966 @default.
- W4378619129 hasConcept C31760486 @default.
- W4378619129 hasConcept C530470458 @default.
- W4378619129 hasConcept C535046627 @default.
- W4378619129 hasConcept C71924100 @default.
- W4378619129 hasConcept C90924648 @default.
- W4378619129 hasConceptScore W4378619129C121608353 @default.
- W4378619129 hasConceptScore W4378619129C126322002 @default.
- W4378619129 hasConceptScore W4378619129C143998085 @default.
- W4378619129 hasConceptScore W4378619129C203092338 @default.
- W4378619129 hasConceptScore W4378619129C204232928 @default.
- W4378619129 hasConceptScore W4378619129C2776694085 @default.
- W4378619129 hasConceptScore W4378619129C2779786085 @default.
- W4378619129 hasConceptScore W4378619129C2781190966 @default.
- W4378619129 hasConceptScore W4378619129C31760486 @default.
- W4378619129 hasConceptScore W4378619129C530470458 @default.
- W4378619129 hasConceptScore W4378619129C535046627 @default.
- W4378619129 hasConceptScore W4378619129C71924100 @default.
- W4378619129 hasConceptScore W4378619129C90924648 @default.
- W4378619129 hasIssue "19" @default.
- W4378619129 hasLocation W43786191291 @default.